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Abstract
The topic of building related illness came into the public’s eye as a major health issue in the mid 1970s, when several cases of
pneumonia were found to be associated with an infectious agent in Philadelphia. This agent was subsequently found to be a
gram-positive bacterium known as Legionella pneumoniae. During the ensuing 30 years, a myriad of symptom constellations,
disorders, clinical syndromes and illnesses have been attributed to indoor living or working environments. Over time, there
appeared to be no limit to claims of building related illness, and it was “reported” that almost any kind of clinical symptom,
real or imaginary, could be blamed on indoor environments. As society became more and more litigious, many of these
disorders were erroneously played out in courtrooms rather than medical ofﬁces, creating a circus atmosphere surrounding
this class of disorders.With the advent of the internet, as well as other advances in telecommunications, these issues eventually
became part of a media frenzy, and all truths could be thrown out the window as issues became more and more decided upon
by emotions and unfounded beliefs, rather than scientiﬁc data and logical thinking.
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Introduction
It has long been known that the environment plays a
role in human health. Generally, environmentally
induced adverse effects fall into several broad
categories, including allergic, infectious, toxic and
psychogenic. The causes of these types of reactions
range from living organisms such as bacteria, viruses
and fungi and their byproducts, to non-living
substances including inorganic, organic and bio-
chemicals such as volatile organic chemicals (VOCs),
poisons and irritants (Chang and Gershwin 2004,
O’Mahony et al. 1989). Examples of these agents are
shown in Table I. In fact, as far back as the sixteenth
century, indoor living environments have been
suspected of causing illness. The Archbishop of
Saint Andrews, John Hamilton, suffering from a
multitude of respiratory symptoms, was diagnosed by
the Italian physician Gerolamo Cardano as being
“allergic” to feathers (Chang and Gershwin 2004).
Removal of the feathers appeared to solve the
problem.
Several factors have contributed to the increased
attention focused on building related illness. The very
fact that allergies and asthma have seen a marked
increase in prevalence over the past thirty years has led
to a heightened awareness of all forms of allergic
disease as real illnesses. In addition, this increase has
been observed to occur mostly in developed countries
and in urban areas of developed countries in
particular. This coincides with a change in living
style in the population of developed countries, partly
as a result of building construction standards; from an
open air type of environment (e.g. farms), to an energy
efﬁcient, tight building type of environment, in which
many of us spend up to 90% of our time. Along with
our propensity to seek out targets to blame for our
misfortune, this led to a fear-induced hysteria which
eventually came to be known as the Sick Building
Syndrome (Chang et al. 1993).
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The Sick Building Syndrome is a poorly deﬁned
clinical entity that is used to describe a constellation of
complaints that occur in groups of ofﬁce workers, in
which the complaints are attributed to being present in
the building (Chang et al. 1993, Ueno et al. 1986,
Chang et al. 1994, Mahmoudi and Gershwin 2000,
Assoulin-Daya et al. 2002, Tsai and Gershwin 2002).
The symptoms described are numerous, and are
frequently different from person to person. These
symptoms have included upper and lower respiratory
complaints such as difﬁculty breathing, wheezing,
coughing, nasal drainage and congestion, sneezing
and tightness in the chest, ocular symptoms such as
r e d ,i t c h yo rw a t e r ye y e s ,a n dam u l t i t u d eo f
neurological complaints ranging from headaches to
difﬁculty concentrating and memory loss. Other vague
systemic symptoms include arthralgias, fatigue and
malaise. Both non-living and living entities have been
blamed in Sick Building Syndrome; these include
VOC, bacterial, viral or fungal organisms and their
byproducts, temperature, vibration, electrostatic
ﬁelds, lighting and environmental tobacco smoke.
Toxic mold syndrome
In the 1980s attention that was originally focused on
Sick Building Syndrome was gradually diverted
toward another form of building related illness, a
new disease entity called “toxic mold syndrome”.
Toxic mold syndrome caught the attention of the
media and the public after an association between
black mold accumulation and perceived occupant
symptoms was observed (Nordness et al. 2003). The
visible mold in question turned out to be a fungi
belonging to the genus Stachybotrys, which is a mold
that causes a black colored build up of spores on
various substrates. Whether or not there is truly a
causal relationship between the two is not yet known,
as there are currently no studies proving that toxins
released by black mold cause the constellation of
symptoms commonly described by patients claiming
to have “toxic mold syndrome” (Chapman et al.
2003). In fact, it is far more likely that an allergic or
immunologic mechanism may be at least partially
responsible for symptoms related to exposure to
Stachybotrys (Edmondson et al. 2005). In no cases is
the data convincing. The data is ﬁlled with exagger-
ations and half-truths.
The truth about mold
The relationship between mold exposure and human
health has been a prevalent issue in recent decades,
and it has been one in which various industries and
professions have been involved, including the legal,
healthcare, home construction and heating and air-
conditioning (HVAC) industries. Like other
extraneous living organisms, such as bacteria and
viruses, fungi can indeed cause a variety of illnesses
ranging from infectious diseases to allergies. Fungi
may also be responsible for a number of occupational
illnesses known as “hypersensitivity pneumonitis”
(Greenberger 2004). It is important to realize that
although fungi may cause illness, not all building
related illnesses or symptoms can be attributed to
fungi simply based on the fact that fungi is present in
the environment. Just because something in the
environment looks “bad” does not mean that it is
necessarily bad for one’s health.
The reason this point must be addressed is because
many of the judgments in mold related litigation cases
are rendered based on appearances and emotion, with
no consideration of the scientiﬁc evidence available.
Often the argument for a causal link between mold
and illness is based solely on the unsightly presence of
mold. This is analogous to saying that a heap of
clothes causes illness because it is untidy. But this
argument is exactly what has driven the hype in recent
years with regard to “mold madness.”
So how does one decipher the mold issue? There
are indeed several topics of discussion with regard to
mold. For example, what are the real illnesses caused
by mold? How do we know this? What are the
illnesses that have been attributed to mold, but have
not been proven to be a result of mold? What is a
“mycotoxin”? Are “mycotoxins” really harmful to
human health? Is a mold buildup in the home
Table I. Environmental agents associated with adverse health
effects in humans.
Allergenic agents
Non-mold indoor allergens
Dust mite
Animal dander—cat, dog, rodent, other household pets
Cockroach
Outdoor allergens
Pollens
Molds
Insects
Drugs
Infectious agents
Fungal
A. fumigatus
Allergic fungal sinusitis
Viral
Bacterial
Pneumocystic carinii
Toxins
Gases
SO2
NO2
Formaldehyde
Radon
Volatile organic compounds
Particulates
Environmental tobacco smoke
Asbestos
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one identiﬁes mold in the building? Are there
standards as to a safe level of mold in a building?
Who cleans up mold-infested buildings? And how do
we educate the public in their knowledge of the true
data on molds? The remainder of this article will be
focused on answering these questions.
Diseases associated with mold exposure
For all the hype and hysteria associated with mold
related disease, the majority of the cases with the
highest publicity are neither mold related nor even
real diseases (Terr 2004). Over the past decade, the
truth regarding the adverse health effects of molds
has become severely distorted by the special interests.
In most circles of discussion, when mold is
mentioned in the context of human health, the ﬁrst
thing that comes to mind are commonly encountered
phrases such as “toxic mold syndrome”, or “black
mold”. The next thing that people think about is that
there is someone to blame for the subject’s
symptomatology, someone that can be held legally
accountable, such as a landlord or a builder. In
actuality, mold related diseases have only been proven
to occur by way of two mechanisms: infectious or
allergic. Of the two, allergic diseases as a result of
mold exposure are by far the most prevalent. Allergic
diseases that can occur as a result of mold exposure
are primarily respiratory in nature, leading to allergic
rhinitis, conjunctivitis or asthma. In order for mold
spores to cause respiratory symptoms, the mold must
be airborne. Thus, contrary to popular belief, the
presence of mold on a wall has by itself no consistent
correlation with health effects.
Indeed, molds are only one category of allergenic
entities that can cause allergy or asthma symptoms.
Other common indoor allergens that are encountered
in indoor environments are shown in Table II, along
with their respective sensitization rates (Gruchalla
et al. 2005). These allergens are generally carried on
particles that are too small (usually less than 10mmi n
diameter) to be seen with the naked eye, and it is only
when those particles are airborne that they present a
human health problem.
Scientiﬁc studies have conﬁrmed that molds can
indeed cause allergies, and a mouse model of lung
allergyinducedbysporesofCladosporiumandAlternaria
species was recently developed. Cladosporium herbarum
and Alternaria alternata spores were shown to be able to
induce the production of speciﬁc IgM and IgG1
antibodies, as well as increasing serum IgE levels.
Mold spore challenge also was demonstrated to induce
airway hyperreactivity in response to methacholine
challenge(Havauxetal.2005).Obviously,ifpatientsare
not allergic (with IgE antibodies) to mold, then they
cannot develop such symptoms.
In contrast to allergen related diseases, the entity
known as “toxic mold syndrome” is poorly deﬁned
clinically, and no mechanism for the pathogenesis of
this disorder has been demonstrated. The symptoms
that make up this disorder vary from patient to patient
and may include respiratory symptoms, headache,
mucous membrane irritation, loss of memory,
difﬁculty concentrating, blurry vision, other neuro-
logical complaints and skin problems. The etiologic
entity for “toxic mold syndrome” is a group of
chemicals known as “mycotoxins”. The term is
derived from “myco,” meaning fungal and “toxikon,”
meaning poison. A practical deﬁnition of the term
“mycotoxin” is a natural product released by fungi
that can evoke a toxic response when presented via a
natural route to other living organisms, in particular,
higher vertebrates (Bennett 1987). Examples of
mycotoxins are shown in Table III. Not all mold
species release mycotoxins. Examples of fungi that do
produce mycotoxins include Aspergillus, Stachybotrys,
Fusarium, Penicillium and Acrimonium (Jarvis and
Miller 2005). Mycotoxins have been shown to be
contaminants of grain and other food products, but
unless eaten will not make people ill (Robbins et al.
2000; Kelman et al. 2004).
Mycotoxins have been studied in vitro in cellular
systems, and have been shown to have a number of
undesired effects on in vitro immune function. EL-4
thymoma cells were found to produce elevated levels of
interleukin-2 (IL-2) when cultured in the presence of
lowlevelsofsatratoxinH,isosatratoxinF,roridinA,and
verrucarin A (Lee et al. 1999). On the other hand, the
level of IL-2 production was reduced at high concen-
trations of these mycotoxins. Also observed was a
cytotoxic effect that was mycotoxin dosage dependent.
Table II. Allergens.
Allergen Sensitization rates(14)* (%)
Dust mite 62
Cockroach 69
Animals
Cat 44
Dog 21
Molds 50
Pollens—tree, weed and grasses
*Of 936 children with moderate to severe asthma enrolled in the
Inner City Asthma Study Group.
Table III. Mycotoxins.
Deoxynivalenol (DON)
Diacetoxyscirpenol
Nivalenol
Satratoxins
T-2 toxin
Trichoverrins
Trichoverrols
Verrucarins
Verrucarol
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proteinandDNAsynthesis(Uenoetal.1968,Uenoand
Fukushima1968,EhrlichandDaigle1987),causebone
marrow suppression in mice (Ryu et al. 1987) and
induceapoptosisofhumanleukemiacells(Nagaseetal.
2001). Mycotoxins have also been found to reduce
production of lung surfactant by rabbit type II alveolar
cells (Mason et al. 2001). Despite these studies, no
adverse effects whatsoever on lung function have been
demonstrated to occur as a result of exposure to
mycotoxins.
One well-deﬁned entity that was associated with
exposure to Stachybotrys (black mold) was infant
pulmonaryhemorrhage.Thisassociationﬁrstsurfaced
in the Cleveland, Ohio area in 1994 (Etzel 2003,
Etzel et al. 1998, Update 1997). Ten infants presented
with pulmonary hemorrhage, with half of them
developing recurrent illness. While exposure to
Stachybotrys was initially thought to be the culprit,
this was never proven in subsequent studies. The
association was also not reproducible in later studies
(Kuhn and Ghannoum 2003, Terr 2001), and the
existence of a cause and effect relationship was further
refuted by the fact that, while Stachybotrys is wide-
spread, infant pulmonary hemorrhage is very rare.
As in the above case, most reports in the literature
regarding mold related illnesses are anecdotal and
often not accurate. In the case of toxic mold
syndrome, studies have failed to prove a relationship
(Hardin et al. 2003).
Infectious diseases resulting from mold exposure
Fungi can also cause infectious diseases, including
allergic bronchopulmonary aspergillosis (ABPA)
(Coop et al. 2004, Malde and Greenberger 2004,
Slavin et al. 2004, Wark 2004), allergic fungal sinusitis
(Luong and Marple 2004), humidiﬁer fever (Pal et al.
1997, Ohnishi et al. 2002), and a group of conditions
known as hypersensitivity pneumonitis (Nacar et al.
2004, Marras et al. 2005, Moore et al. 2005). The
fungus most commonly blamed for ABPA isAspergillus
fumigatus. The diagnosis can be supported by ﬁnding
an elevated level of speciﬁc IgE to A. fumigatus, skin
test positivity to A. fumigatus, and by direct culture.
In contrast, no fungal species has been causally linked
to humidiﬁer fever. Both humidiﬁer fever and
hypersensitivity pneumonitis present with respiratory
symptoms of chest tightness and dyspnea, and other
ﬂu-like symptoms such as fever, chills and malaise.
Hypersensitivity pneumonitis is associated with
occupational asthma, and is described in patients
exposed to organic dust. Farmer’s lung, pigeon
breeder’s disease and mushroom worker’s disease are
examples of hypersensitivity pneumonitis. Although
fungi such as Micropolyspora faenia and Actinomycetes
species have been blamed for hypersensitivity
pneumonitis, no deﬁnitive causal relationship has
been found.
Non-health related mold hazards
Diseases proven to be caused by mold include allergies
and asthma. But the fact that we have no proof of toxic
mold syndrome or infant pulmonary hemorrhage
being caused by mold does not mean that mold
buildup in homes is harmless. Visible mold may be an
indicator of water intrusion into the building, which
can damage walls and create structural instability.
Moreover, still water collections can also be a medium
for the growth of other organisms and may even be a
harbor for disease carrying insects like mosquitoes.
Increased humidity can also lead to an increase in dust
mite exposure, and allergies and asthma symptoms
may worsen. Cockroaches also need moisture to
survive, and cockroaches have been found to be major
contributors to allergy and asthma symptoms,
particularly in high-density urban environments.
Cockroaches are an indication of poor hygienic
conditions, and also poor upkeep of the building.
It may eventually be shown that the presence of mold
may serve more as an indicator of conditions that are
conducive to increasing the risk of exposure to other
allergens or infectious agents, rather than itself being
harmful to human health.
Sampling of mold
There are generally three ways to sample for mold in
indoor environments. The ﬁrst way is to measure
airborne levels of mold. This is the most accurate
reﬂection of exposure, because most mold allergies are
mediated via a respiratory route. The symptoms
experienced by patients suffering from airborne
allergies usually result from inhalation of airborne
particles containing these allergens, and include nasal
and ocular pruritis, sneezing, rhinitis and nasal
congestion, ocular erythema, as well as lower respir-
atory tract symptoms in asthmatics, such as coughing,
wheezing and shortness of breath. Techniques have
been developed to collect mold samples from both
airborne and surface sources. Airborne samples are
collected by using a vacuum pump attached to a
compartment holding a collection surface on which
particles are deposited, such as a microscope slide for
the collection and analysis of non-viable plus viable
mold spores, or culture plates for the collection of
viable spores only. An example of such devices include
the Burkhard sampler, which is a self driven unit
consisting of both a vacuum pump and an analysis
chamber; another is a simple GAST pump connected
to an Anderson sampler. Sampling rates differ for
collectionofviableversusnon-viablesamples(15l/min
for viable and 28.6l/min for non-viable). The pumps
are usually run for 3–5min. Direct visualization of the
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the genus, and further speciation can be done using
culturetechniques.Surfacesamplesarecollectedusing
either a tape lift or a swab sample and are more useful
for qualitative analysis of the type of mold species
present, or for speciation. The third way to analyze
mold in the environment is by taking a bulk sample
from carpet dust using a standard vacuum cleaner.
In the case of Aspergillus or Alternaria, enzyme linked
immunosorbent assays (ELISAs) can be used for
quantiﬁcation of the amount present in bulk samples,
as when analyzing other non-mold allergens.
A meaningful assessment of indoor mold levels
Ingeneral,indoorlevelsofmoldshouldreﬂectoutdoor
levels. The source of most indoor mold is ultimately
what is present outdoors. Outdoor airborne levels of
molds can vary signiﬁcantly based on climate,
temperature and relative humidity, foliage, the pre-
sence of environmental substrates for mold growth,
etc. But whatever the concentration of spores out-
doors, the indoor environment presents no additional
healthhazardtoanoccupantiftheindoorlevelsareless
than or equal to the outdoor levels. It is therefore
meaningful, at least when addressing allergies and
asthmaresultingfrommolds,touseanindoor/outdoor
ratio when evaluating the risk of exposure to indoor
mold spores (O’Connor et al. 2004). If indeed the
indoor levels of various mold species is different from
theoutdoorlevels,eitherqualitativelyorquantitatively,
thenonemustconcludethatthereisanalternatesource
of mold growth. This most often reﬂects a difference
between the indoor and outdoor environments, which
usually means that there is an abnormal source of
moisture that facilitates mold growth, such as a water
leak, or a general increase in humidity. When such a
condition is found, then the nature of the difference
must be deﬁned. Whether or not such a difference
actually is responsible for patient symptoms is yet
another matter, as discussed below.
Relationship between environmental presence
of an allergen and patient symptoms
Even if mold levels are elevated indoors when
compared to outdoor levels, this does not prove that
moldsarerelatedtoanoccupant’sillness.Inthecaseof
allergies, the occupant must exhibit signs that are
consistent with allergies, and they must also test
positive to the same molds that are found in the
environment during RASTor skin testing. If this is not
the case, then mold allergiesare notresponsible for the
patient’ssymptoms.Inthecaseofaninfectiousdisease,
theremustbeadocumentedinfection,suchassinusitis
or pneumonia. Such an infection can be documented
radiographically, by a complete history and physical
andbysurgicalretrievalofculturesamplesfromthesite
ofinfection.Inaddition,isolationoftheorganismfrom
the site ofinfection should also beconsistentwith what
is found in the environment. If this is not found to be
the case, then an infectious process due to mold can be
ruled out. Vague symptomatology such as headache,
malaise, fatigue or difﬁculty thinking simply is not
sufﬁcient to establish a cause and effect relationship.
If,afterathoroughevaluationofthepatient’scondition
and environment, as illustrated above, the occupant is
not allergic to mold, and there is no evidence of a mold
infection, nor any evidence that the particular mold in
question causes infection, then it is possible that mold
is not the issue at all, regardless of what is observed or
even what is measured in airborne samples.
Issues regarding regulation of indoor air quality
and certiﬁcation of mold specialists
Recently, many states have begun to set certiﬁcation
standards for mold inspection and remediation
specialists. Legislation already exists in New York
regarding indoor mold exposure safety limits, and
California is in the process of adopting a bill known as
the “Toxic Mold Act of 2001”, in which standards will
be introduced regarding safe indoor levels of mold
exposure. Budget considerations have delayed the
introduction of such a bill. In Florida, HB117 was
introduced and requires that all mold remediation
professionalsbetrained,licensedandcertiﬁed.Whileit
is admirable that regulations are being proposed to
protect individuals from indoor health issues, one
would hope that standards are not being arbitrarily
introduced based on public hysteria, and that they
wouldbebasedonevidenceandfoundedongoodbasic
scienceandclinicalstudiesthatareplacebo controlled,
peerreviewedandreproducible(Anyanwuetal.2004).
Currently, the insurance industry standard is to
exclude mold related problems from most home
insurance policies. State and federal legislation is
being enacted to pass laws regarding mold testing and
insurance (Barrett 2003). When purchasing a home or
home insurance, it is important for the prospective
buyer tobe aware oftheir coverage pertaining to mold-
induced health or building problems.
At the present time, given the level of our current
knowledge regarding mold related illness, there is no
possibility of reaching a consensus on what constitutes
a safe absolute level of airborne mold spores (Bobbitt
et al. 2005). In fact, if we consider mold exposure as a
potential health hazard only from an allergy stand-
point, the only number that may be meaningful is the
ratio between outdoor and indoor levels.
Relating patient symptoms and environmental exposures
The ﬁrst step in identifying a building related illness is
to evaluate the patient’s symptoms. If the patient
develops increased symptoms while in the building,
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environmental problem. This in itself does not deﬁne
thecauseofthesymptoms,nordoesitclarifywhattype
of illness the patient may have. If the symptoms
complex is consistent with allergic diseases, then
evaluation of the patient for speciﬁc allergies and a
search for an environmental trigger should be
undertaken. If the symptoms are consistent with an
infectious disease, the source may be viral, bacterial or
fungal, but may or may not be related to occupancy of
the building, as infectious symptoms typically do not
wax and wane once an exposure has occurred.
If symptoms cannot be attributed to a speciﬁc
condition, or if the symptoms are poorly deﬁned and
highly subjective, then there is a high probability that
psychosomatic factors may play a role. For example,
symptoms such as difﬁculty concentrating are not
typically caused by an allergic mechanism.
Investigationoftheenvironmentisanimportantfacet
of managing allergic disease. An analysis of the
environment for allergens should not be restricted to
molds,butshouldincludeasearchforalloftheallergens
listed in Table II. The allergenic proﬁle of the patient
should be correlated with exposure patterns. If molds
are indeed identiﬁed as a trigger for the patient’s
allergies, if the same allergens are found in the
environment, and if the indoor mold counts differ
signiﬁcantly from the outdoor mold counts, then a
searchforanindoorsourceoftheoffendingmoldcanbe
undertaken. An inspection of the building usually
identiﬁes this problem. Once the source is found,
remediation can ensue.
Mold remediation
There are two separate aspects to mold remediation.
Theﬁrstishealthrelated,andpertainstoanyallergyor
asthma symptoms that may be present in an occupant
of a building. If host-environmental relationships ﬁt,
then measures should be undertaken to remove the
offending mold from the environment. Usually, this
can be done by identifying the source of the moisture
that is facilitating mold growth. If this is a water leak,
repairs may be necessary. Other than that, certain
environmental measures can help keep mold levels
down, including adjustment of the relative humidity of
the home,andremoval ofpotential substratesfor mold
growth such as damp books, rotting wood, decaying
food, etc. Once correction measures have been
implemented, airborne mold levels should be re-ana-
lyzed. The patient should also be closely monitored by
his or her physician to ensure that remedial measures
produce the desired improved patient outcomes.
Qualityoflifeassessmentsshouldbedoneperiodically,
and correlated with the patient’s environmental
exposure. This type of positive feedback seems to
provide an additional intangible beneﬁt as it increases
patient compliance.
There are several home based programs of
environmental avoidance which involve control
measures for diminishing exposure to indoor aller-
gens, including the use of mattress encasings, HEPA
ﬁlters, removal of animals, frequent washing of bed
sheets and maintaining hygienic conditions. Results
from studies concerning the effectiveness of such
home based programs have been extremely promising.
When environmental control measures are utilized, it
has been demonstrated that allergen loads can be
signiﬁcantly decreased, and an improvement in
asthma symptoms has also been shown to occur
(Morgan et al. 2004, Crain et al. 2002).
Summary
So what is the “origin” of the hoax? What created and
fueled the existence of the past two decades of “mold
Table IV. A sampling of mold-litigation cases.
Year Case Issue Disposition
2001 Ballard vs. Fire
Insurance Exchange
Stachybotrys and mycotoxins
and disclosure issues
Jury verdict in favor of plaintiffs for
$32 million, including $12 million in
punitive damages and $8.9 million in
legal fees
1999 MacDonald vs. Dufferin-Peel
Catholic District School Board
Exposure to toxic
mold resulted in ailments
Seeking $1 billion in general damages,
$500 million in special damage costs
and an additional $500 million in
damages to parents
2001 Erin Brockovich vs. Robert Selleck Water intrusion led to growth of
mold, adverse health effects from the
exposure, Brockovich sued former
owner Selleck
Symptoms probably a result of indoor
pet allergens (Brockovich’s own dog)
1999 New Haverford Partnership, et al.
vs. Elizabeth Stroot
Exposure to various mycotoxins Jury awarded $1 million in damages
to Stroot; verdict upheld on appeal
1997 Doe Homeowners vs. Roe Seller Toxic mold caused bodily injury and
property damage
Case settled for $1.3 million
C. Chang & M. Eric Gershwin 156hysteria?” In all probability, there was not one single
reason why this has mushroomed so out of control.
We live in a very litigious society, and we are quick to
apply blame to others, regardless of guilt. In addition,
many of us live in fear of one thing or another, and
issues tend to be sensationalized based on this fear.
In this case, the fear is that something “ugly”
(i.e. mold growth) is going to harm us in some way.
Sufﬁce to say that mold hysteria did not arise out of
scientiﬁc knowledge or clinical studies. Even to this
day, court judgments, jury decisions and awards are
based on emotion and junk science (Lees-Haley
2003). Literally thousand of mold cases have been
brought forth, and heavy settlements and judgments
have been awarded, the only commonality of which is
the conspicuous absence of any scientiﬁc evidence.
A sample of landmark mold litigation cases is
illustrated in Table IV. The entire current situation
regarding mold-related illness is unfortunate as it
detracts from the truth about mold.
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